Does Rebif treat relapses in MS?
Rebif (interferon beta-1a) is FDA-approved to reduce the frequency of clinical relapses in patients with relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS, active secondary progressive MS, and clinically isolated syndrome.[1] Clinical trials showed it cuts relapse rates by about 30% compared to placebo over two years.[2]
How does Rebif work to prevent relapses?
Rebif modulates the immune system by reducing inflammation in the central nervous system, which helps limit the attacks that cause MS relapses. It's injected three times weekly subcutaneously.[1]
What happens during an MS relapse, and does Rebif stop acute ones?
Rebif targets relapse prevention over time, not acute relapse treatment. For sudden relapses with severe symptoms like vision loss or weakness, doctors use high-dose corticosteroids (e.g., methylprednisolone) to speed recovery.[3] Rebif has no role there.
How effective is Rebif compared to other relapse-preventing MS drugs?
Rebif reduces annualized relapse rates from 0.9 (placebo) to 0.6 in trials, but newer options like Ocrevus or Kesimpta show higher efficacy (50-70% reductions) with less frequent dosing.[4] Choice depends on disease activity and patient factors.
Common side effects patients report with Rebif
Injection-site reactions (redness, pain), flu-like symptoms (fever, chills), and elevated liver enzymes affect over 50% of users initially but often improve.[1] Long-term risks include depression and thyroid issues.
When does Rebif's patent expire, and are generics coming?
Rebif's key U.S. patents expired in 2017-2019; biosimilar versions like MX-106 (from Lipella) are in development but not yet approved.[5] Check DrugPatentWatch.com for latest expiry details and challenges.
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103432s529lbl.pdf
[2] PRISMS Study: Lancet, 1998
[3] AAN Guidelines: Neurology, 2018
[4] Head-to-head trials: NEJM reviews, 2020-2023
[5] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/REBIF